GlassScriptPhysician profile
Suman B Rao
NPI 1912976325
$54,058.90
in general payments reported to CMS, 2019-2025
20 companies · $2,781 in 2025
The $2,781 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $10K · 2021: $6,637 · 2022: $2,690 · 2023: $17K · 2024: $2,581 · 2025: $2,781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Consulting Fee: $2,680 · Food and Beverage: $1,183 · Travel and Lodging: $423 · Education: $77.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,200.00 |
| Consulting Fee | $2,680.00 |
| Food and Beverage | $1,182.78 |
| Travel and Lodging | $423.46 |
| Education | $77.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $40,097.19 | 2019-2024 | Tagrisso, Imfinzi, Calquence |
| Daiichi Sankyo INC. | $2,714.26 | 2022-2025 | Enhertu |
| Roche Diagnostics Corporation | $2,600.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $2,532.19 | 2020-2022 | |
| Emd Serono, INC. | $2,285.00 | 2021 | |
| Seagen INC. | $1,394.75 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $1,106.87 | 2020-2024 | Keytruda |
| Genentech USA, INC. | $870.74 | 2019-2023 | Phesgo, Tecentriq |
| Gilead Sciences, INC. | $159.72 | 2021-2023 | Trodelvy |
| Caris Mpi, INC. | $83.48 | 2025 | Mi Cancer Seek |
| Genentech, INC. | $79.86 | 2023 | Lunsumio |
| Mirati Therapeutics, INC. | $77.12 | 2023-2024 | Krazati |
| Pfizer INC. | $20.57 | 2022 | |
| Abbvie INC. | $20.13 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2025 | Libtayo |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suman Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.